EGFR and non-small cell lung carcinoma: Overexpression and activation of Met have been reported frequently in advanced non-small cell lung cancers with resistance to EGFR inhibitors or antibodies.50 Therefore, Met may play an important role in drug resistance and metastasis rather than EGFR.